CAFE B
Platinum Partner
Green Nephrology Partner
Platinum Partner
Green Nephrology Partner
Gold Partner
Green Nephrology Partner
Gold Partner
Green Nephrology Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Silver PartnerA
BOOTH G2
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
View:
Committing to a sustainable future video
Download
Understanding Anaemia and Aranesp
2027 Goals Infographic Outlined
BOOTH 7
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge medicines for rare metabolic diseases.
BOOTH 6
The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) is a clinical quality registry that collects and produces a wide range of statistics relating to the outcomes of treatment of those with end stage kidney failure. ANZDATA has been in operation since 1977 and all dialysis and transplant services, in Australia and New Zealand, contribute data to The Registry.
ANZDATA’s fundamental purpose is to report on the incidence, prevalence and outcomes of dialysis and transplant treatment for patients with end stage kidney disease across Australia and New Zealand.
The ANZDATA Registry operates under the South Australian Health and Medical Research Institute (SAHMRI) – ABN 54 141 228 346.
Our Registry office is located on Level 4 South of the SAHMRI building, on North Terrace, in the Medi-Precinct of Adelaide, South Australia, Australia.
BOOTH 3
The Australian and New Zealand Society of Nephrology is a not-for profit organisation representing the interests of health professionals committed to the prevention and treatment of kidney disease. Through the ANZSN, members support a range of research, education and clinical care initiatives to promote evidenced based practice and quality outcomes for patients in Australia, New Zealand and our region.
BOOTH P2
AstraZeneca strives to consistently be the number one company in Australia for companies to partner and collaborate with. Across our biologics and small molecule research, we are concentrating our scientific efforts and the weight of our investment, including business development, on three core therapy areas:
- Cardiovascular and Metabolic Disease (CVMD)
- Respiratory, Inflammation & AutoImmune (RIA)
- Oncology
B
BOOTH G1
BOOTH G5
At Baxter, we are firmly committed to supporting healthcare providers and renal patients by providing world-class products, service, and support at home or in the clinic. For more than 60 years we have partnered with the nephrology community to pioneer care in both haemodialysis (HD) and peritoneal dialysis (PD). We maintain that pioneering spirit today through our unparalleled innovation including remote patient management via our Sharesource platform and new therapies like expanded haemodialysis (HDx).
Sharesource has been documented to simplify the delivery of care and improve patient outcomes using a two-way, cloud-based technology for PD patients. Sharesource creates a connected home therapy experience that is a safe and effective way to manage patients remotely.
HDx takes us a step closer to the natural kidney and represents a unique and significant advance in haemodialysis. HDx demonstrates superior removal of large middle molecules (25kDa to <60kDa), many of which are linked to the development of inflammation, cardiovascular disease, and other co- morbidities in dialysis patients. HDx opens a new door for dialysis patients with a determined effort to improve patient outcomes past the limitations of current dialysis technology.
As Australia’s only local manufacturer of “Australian Made” peritoneal dialysis solutions, we are proud
to invest in local medical innovation and support local hospitals, healthcare professionals and patients. Baxter Renal Care … pioneering dialysis therapies to save and sustain lives.
BOOTH S1
Two companies; one commitment to patient care. Since 2012, Boehringer Ingelheim and Eli Lilly
as an Alliance have brought to market a number of new therapies, based on years of research
and development. Supporting multiple international clinical trials, new evidence has been
generated to improve the management and outcomes for patients with type 2 diabetes and
now patients with chronic heart failure. By partnering with the medical and healthcare
community, we will continue to contribute to these improvements as two companies, with one
commitment to better serve people living with these conditions.
Find out more at www.boehringer-ingelheim.com.au and www.lilly.com.au
C
BOOTH G3
CSL Vifor in Australia is a leader in iron deficiency and has a rapidly growing presence in nephrology. We are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease. Our focus in nephrology is supported by our expertise in iron deficiency therapy, helping to support a broad range of patients in need.
CSL Vifor in Australia is proud to sponsor local medical education and invest in research and development to help patients lead better, healthier lives.
F
BOOTH P1
Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure. Around 3.7 million patients with this disease worldwide regularly undergo dialysis treatment. Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure.
We care for more than 346,000 patients in our global network of more than 4,000 dialysis clinics. At the same time, we operate 44 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
In Australia, Fresenius Medical Care has been caring for patients undergoing dialysis as a result of chronic kidney failure for more than a decade. As a result, we intimately understand the impact chronic kidney failure has on people’s lives. And we are committed to providing outstanding patient care that goes beyond innovative dialysis products and therapies. We care for each patient’s individual situation, whether they want to stay in their familiar surroundings at home or receive dialysis in one of our 23 clinics across the country.
G
BOOTH G6 and 1
GSK is a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better and live longer.
In Australia, we offer a broad portfolio of innovative and established vaccines and medicines in respiratory disease, HIV and oncology.
K
BOOTH 2
We are the peak body for kidney health in Australia. For over 50 years, we have connected people to the vital information, education and support services they need to preserve their kidney health and live a better quality of life if they are diagnosed with kidney disease. We work with a range of stakeholders and community groups to drive innovations and improvements in the management of kidney disease, so that one day every Australian can enjoy good kidney health.
N
BOOTH 10
Nipro is a leading global healthcare company dedicated to developing and delivering innovative and patient-oriented products for healthcare professionals, patients and the pharmaceutical industry. Our divisions include diabetes care, hospital, renal care, infusion devices and needles and syringes. Renal care includes a full PPT portfolio of; Surdial X dialysis machines and their blood tubing sets, Elisio and Solacea dialysers, Nipro AVFs, Niprocart and Niprosol. Nephroflow AV Access Monitor and Hemo RO 4 One Reverse Osmosis machines are also available. New in 2022, Nipro is introducing our ne “Sharp cut-off” MCO HX Elisio Dialyser.
O
BOOTH 8
Otsuka has always had a philosophy of developing and delivering drugs for diseases where there is an unmet medical need. In Nephrology, that philosophy is particularly apt. Our main focus in this area is autosomal dominant polycystic kidney disease (ADPKD), an inherited disease in which fluid-filled cysts grow in the kidneys, impairing kidney function and often eventually resulting in kidney failure. Otsuka developed the first disease modifying medication for ADPKD.
P
BOOTH G4
Pharmacor is an Australian-grown and operated competitor in the fast-growing generic medicine market. Established in 2007, Pharmacor specialises in complex fixed dose formulations and offers a wide range of prescription and OTC medicines to Australian pharmacies and hospitals. Our mission is to become the leader in providing first-to-market generics within Australia. To accomplish this, we are working diligently with our research and development partners to ensure timely access to high-quality generic medicines.
Through our association with Alkem Laboratories, we have a vision for a sustainable and equitable healthcare system that will provide Australians with timely access to affordable generic medicines. Our strength lies in our research & manufacturing facilities that are both TGA & FDA approved. We use high-quality ingredients produced by certified manufacturers which ensures that our medicine is both safe and effective. We are committed to offering affordable substitutes to nephrology patients and alleviating hospital budgets while providing identical medical results.
R
BOOTH 4
As part of a global movement, Evolve is a flagship initiative led by physicians, specialties and the Royal Australasian College of Physicians (RACP) to drive high-value, high-quality care in Australia and New Zealand. Evolve works with specialties to identify their ‘Top-Five’ clinical practices that are considered low-value.
T
BOOTH 5
The Australasian Kidney Trials Network (AKTN) operates under the Centre for Health Services Research at the University of Queensland’s Faculty of Medicine and is located at the Princess Alexandra Hospital campus, Woolloongabba.
It is a not-for-profit research organisation that designs, conducts and supports investigator-initiated clinical trials with the aim of improving life for people with Chronic Kidney Disease (CKD). It consists of a group of Nephrologists and other doctors, nurses, researchers, dieticians, scientists and other health professionals who conduct clinical trials in kidney disease. Because of their interest in kidney disease and kidney health, they want to find better treatments for people living with kidney disease. All AKTN clinical trials are designed with patients with kidney disease in mind. A patient with kidney disease sits on the Scientific Committee as a consumer representative to ensure AKTN trials consider quality of life, symptoms and treatments important to people with kidney disease.
BOOTH 4
The George Institute for Global Health is an independent medical research institute aiming to improve the health of millions of people worldwide by generating effective, evidence-based and affordable solutions to the world’s biggest health challenges. Established in Sydney, with major centres in China, India and the UK, it has projects in more than 45 countries and affiliations with world-class universities. In 2018, The George Institute was ranked the number-one independent research institute in Australia by Times Higher Education.
